Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / South Carolina

Peptide legality · South Carolina · updated 2026-09-21

Are peptides legal in South Carolina?

Restricted

South Carolina is restricted: on top of the federal floor, the South Carolina Board of Medical Examiners issued a notice in mid-August 2026 stating that licensed clinicians may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved research-grade peptides to patients.

Legal status overview

South Carolina is restricted because it went beyond the federal baseline: the South Carolina Board of Medical Examiners told licensed providers in mid-August 2026 that they may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved research-grade peptides, and it extended that limit to advanced practice nurses and physician assistants. The notice added that patient consent forms calling a product research-grade do not reduce professional or legal liability, and that only prescription-quality material may be used in compounding. FDA-approved peptide medicines, such as Wegovy® (semaglutide) and approved somatropin products, remain legal when a licensed provider prescribes them appropriately. Compounded peptides are not FDA-approved, not a generic, and not evaluated by the FDA, and in South Carolina they must use prescription-quality active ingredient through a licensed 503A pharmacy or 503B outsourcing facility.

Key points

  • In mid-August 2026 the South Carolina Board of Medical Examiners stated that licensed clinicians may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved research-grade peptides to patients. [1]
  • The Board extended the restriction to advanced practice nurses and physician assistants, closing the delegation loop so it cannot be bypassed through supervised providers. [1]
  • The notice made clear that patient consent forms labeling a product research-grade do not mitigate or eliminate professional or legal liability. [1]
  • South Carolina flagged facilities marketing semaglutide salt forms and research-grade powders that are not FDA-approved, and directed that only prescription-quality material be used in compounding. [1]
  • FDA-approved peptide drugs, including Wegovy® (semaglutide) and approved somatropin products, remain legal in South Carolina when prescribed by a licensed clinician for an appropriate indication. [3]
  • Compounded peptides are not FDA-approved, not a generic, and not evaluated by the FDA; with the GLP-1 shortages resolved, compounding is limited to documented patient-specific need through a licensed pharmacy or outsourcing facility. [2]
  • BPC-157 left FDA's Category 2 do-not-compound list in April 2026 but was not moved to the permitted list, so it still cannot be lawfully compounded, and South Carolina's research-grade prohibition reinforces that limit. [5]
  • Human growth hormone (somatropin) is further restricted by federal law: distribution for uses the FDA has not authorized is a crime under 21 U.S.C. 333(e), which applies in South Carolina. [6]

Compound-by-compound status

BPC-157
Restricted
Not on FDA's permitted 503A bulk substances list and captured by South Carolina's research-grade peptide prohibition; not lawfully compoundable for patients in the state today.
GLP-1 class (semaglutide, tirzepatide)
Restricted
Brand products such as Wegovy® (semaglutide), Ozempic® (semaglutide), and Zepbound® (tirzepatide) are legal by prescription; compounded versions are not FDA-approved, not a generic, and not evaluated by the FDA, and South Carolina requires prescription-quality active ingredient, not research-grade powders or unapproved salt forms.
TB-500 (thymosin beta-4)
Restricted
No FDA-approved human product and treated as a non-approved research-grade peptide, so it cannot lawfully be compounded, prescribed, or administered to patients in South Carolina.
Growth hormone / somatropin
Restricted
FDA-approved somatropin is legal by prescription for approved indications only; distribution for non-approved uses is prohibited under federal law 21 U.S.C. 333(e).

Frequently asked questions

Is BPC-157 legal in South Carolina?

No, not for patient use. It is not on FDA's permitted compounding list, and the South Carolina Board of Medical Examiners' mid-August 2026 notice bars clinicians from compounding, prescribing, or administering non-FDA-approved research-grade peptides, which covers BPC-157. This is information, not legal or medical advice.

Did South Carolina change its peptide rules recently?

Yes. In mid-August 2026 the South Carolina Board of Medical Examiners issued a notice restricting non-FDA-approved research-grade peptides and extended it to advanced practice nurses and physician assistants.

Can I get compounded semaglutide in South Carolina?

Only under narrow conditions. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA. The state requires prescription-quality active ingredient, not research-grade powders or unapproved salt forms, and the shortage-era compounding discretion has ended.

Do patient waivers protect a provider who uses research-grade peptides?

No. South Carolina's notice states that consent forms identifying a product as research-grade do not mitigate or eliminate professional or legal liability.

Are FDA-approved peptide medications still legal here?

Yes. Approved products such as Wegovy® (semaglutide) and approved somatropin medicines remain legal in South Carolina when prescribed by a licensed clinician for an appropriate use.

General information based on the sourced research above, not legal advice. For a specific situation in South Carolina, consult a licensed attorney familiar with pharmaceutical law.